ABU DHABI (The Thursday Times) — Abu Dhabi’s hospitals and research centres notched a run of medical and scientific firsts in the first quarter of 2026, from an AI programme that helps diagnose multiple sclerosis to plans for a cancer therapy facility that would be the first of its kind in the Middle East — a quieter but no less significant marker of the emirate’s push to become a serious hub for precision medicine.
The most immediately useful of the developments is an AI-powered MRI programme launched jointly by the Abu Dhabi Stem Cells Centre, Yas Clinic and NYU Abu Dhabi, aimed at speeding up and sharpening the diagnosis of multiple sclerosis — a disease that is notoriously difficult to catch early because its symptoms mimic those of other neurological conditions.
A cancer therapy first for the region
The more ambitious project on the horizon is a planned heavy-ion radiotherapy facility, announced by M42 in partnership with Cleveland Clinic Abu Dhabi. If completed as planned, it would be the first facility of its kind in the Middle East, offering a form of precision radiotherapy that can target tumours with less damage to surrounding tissue than conventional radiation — a technology currently available in only a handful of centres worldwide, mostly in Japan, Germany and the United States.
“Abu Dhabi is positioning itself to lead the future of medical care through innovative technologies,” the emirate’s health officials said as the quarter’s developments were announced around World Health Day.
On the research side, Mohammed Bin Rashid University of Medicine and Health Sciences published what researchers describe as the first comprehensive Arab genomic reference — a dataset intended to correct a long-standing gap in global genomic medicine, where reference datasets have historically been built overwhelmingly from European and East Asian populations, leaving genetic variants common in Arab populations under-studied and sometimes misclassified.
Genomics and robotics, moving in tandem
Dubai Health researchers added to that body of work with a study published in Nature Communications on genomic medicine for rare diseases, part of a broader regional effort to apply genomic sequencing to conditions that are individually rare but collectively affect a meaningful share of the population — including several genetic disorders newly described in Abu Dhabi children during the same quarter, work that may eventually support gene-therapy approaches for conditions that currently have none.
Alongside the research announcements, Abu Dhabi has continued expanding its use of AI-assisted robotic surgery through 2026, part of a wider pattern rather than a single flagship project: robotics in the operating theatre, AI in the reading room, and genomics in the lab, all advancing on parallel tracks.
The policy underneath it
None of this is happening by accident. A new federal drug-regulation law, Federal Decree-Law No. 38 of 2024, has given the sector a clearer legal foundation for trialling and approving the kind of advanced therapies that heavy-ion radiotherapy and gene-based treatments depend on — the unglamorous regulatory groundwork that tends to determine whether ambitious medical projects actually reach patients or stay stuck in pilot programmes.
Taken individually, none of the quarter’s announcements would make international headlines on its own. Taken together, they describe a health system that is trying to compete not on the number of hospital beds it can build, but on the kind of medicine only a handful of countries can currently offer — a far more difficult, and more interesting, ambition.∎
